Financial Snapshot

Revenue
$58.90M
TTM
Gross Margin
68.22%
TTM
Net Earnings
-$35.19M
TTM
Current Assets
Q3 2024
Current Liabilities
Q3 2024
Current Ratio
637.34%
Q3 2024
Total Assets
Q3 2024
Total Liabilities
Q3 2024
Book Value
-$45.42M
Q3 2024
Cash
Q3 2024
P/E
-11.17
Dec 02, 2024 EST
Free Cash Flow
-$34.37M
TTM

Revenues

Revenues

Loading...

Revenue YoY Change

Loading...

Revenues

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Revenue $50.58M $47.68M $50.83M $45.85M $52.61M $67.43M $66.92M $51.79M $2.720M $2.120M $2.050M
YoY Change 6.09% -6.2% 10.87% -12.85% -21.98% 0.76% 29.21% 28.3% 3.41% 2462.5%

Expenses

Cost Of Revenues

Loading...

Gross Profit

Loading...

Gross Profit Margin

Loading...

Gross Profit

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Revenue $50.58M $47.68M $50.83M $45.85M $52.61M $67.43M $66.92M $51.79M $2.720M $2.120M $2.050M
Cost Of Revenue $20.83M $19.39M $14.99M $12.96M $20.36M $20.99M $19.82M $16.38M $1.620M $1.280M $1.390M
Gross Profit $29.75M $28.29M $35.84M $32.89M $32.25M $46.44M $47.10M $35.41M $1.090M $840.0K $660.0K
Gross Profit Margin 58.82% 59.34% 70.51% 71.72% 61.3% 68.87% 70.38% 68.37% 40.07% 39.62% 32.2%

Selling, General & Admin Expense

Loading...

Research & Development

Loading...

Depreciation, Depletion & Amortization

Loading...

SGA Expense to Gross Profit Ratio

Loading...

R&D To Gross Profit Ratio

Loading...

DDA To Gross Profit Ratio

Loading...

Operating Expenses Total

Loading...

Operating Profits/Loss

Loading...

Operational Expenses

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Selling, General & Admin $31.75M $52.88M $53.48M $55.89M $64.34M $72.27M $25.08M $20.80M $11.30M $7.370M $3.170M
YoY Change -39.96% -1.11% -4.32% -13.13% -10.97% 188.15% 20.58% 53.32% 132.49% 604.44%
% of Gross Profit 106.72% 186.89% 149.19% 169.96% 199.52% 155.62% 53.25% 58.74% 1036.7% 877.38% 480.3%
Research & Development $13.10M $17.48M $17.05M $19.89M $20.57M $23.11M $22.13M $15.45M $1.990M $1.260M $1.010M
YoY Change -25.04% 2.55% -14.28% -3.34% -10.98% 4.44% 43.24% 57.94% 24.75% 27.85%
% of Gross Profit 44.04% 61.78% 47.56% 60.47% 63.8% 49.77% 46.99% 43.63% 182.57% 150.0% 153.03%
Depreciation & Amortization $1.153M $2.270M $2.912M $3.392M $2.854M $3.186M $3.800M $3.890M $1.970M $720.0K $520.0K
YoY Change -49.21% -22.05% -14.15% 18.85% -10.42% -16.16% -2.31% 173.61% 38.46%
% of Gross Profit 3.88% 8.02% 8.12% 10.31% 8.85% 6.86% 8.07% 10.99% 180.73% 85.71% 78.79%
Operating Expenses $44.85M $70.36M $85.51M $88.74M $105.3M $116.4M $47.21M $36.26M $13.29M $8.630M $4.180M
YoY Change -36.25% -17.72% -3.64% -15.71% -9.53% 146.49% 30.2% 54.0% 106.46% 234.4%
Operating Profit -$15.10M -$42.07M -$34.68M -$42.89M -$52.67M -$48.93M -$110.0K -$850.0K -$12.20M -$7.790M -$3.520M
YoY Change -64.1% 21.3% -19.15% -18.56% 7.63% 44385.45% -87.06% 56.61% 121.31% 188.52%

Interest Expenses

Loading...

Interest Expenses To Operating Income %

Loading...

Other Expense/Income

Loading...

Interest & Other Expense/Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Interest Expense $6.337M -$12.34M $10.05M $11.06M $9.318M $7.711M -$8.830M -$6.890M -$620.0K -$540.0K -$40.00K
YoY Change -151.34% -222.84% -9.17% 18.74% 20.84% -187.33% 28.16% 14.81% 1250.0%
% of Operating Profit
Other Income/Expense, Net -$1.125M -$10.00K $0.00 -$100.0K $60.00K $40.00K $0.00
YoY Change -100.0% 50.0%

Income/Loss

Pretax Income

Loading...

Income Tax

Loading...

Net Profits/Loss

Loading...

Pretax Income YoY Change

Loading...

Income Tax Rate

Loading...

Net Profits/Loss YoY Change

Loading...

Basic EPS

Loading...

Net Income To Revenue Ratio

Loading...

Pretax & Net Income

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Pretax Income -$7.625M -$54.41M -$70.54M -$55.78M -$66.25M -$61.38M -$8.940M -$9.600M -$12.75M -$8.280M -$3.560M
YoY Change -85.99% -22.87% 26.45% -15.79% 7.93% 586.53% -6.88% 53.99% 132.58% 191.8%
Income Tax $245.0K $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$7.870M -$54.41M -$70.54M -$55.78M -$66.25M -$61.38M -$8.940M -$9.600M -$12.75M -$8.280M -$3.560M
YoY Change -85.54% -22.87% 26.45% -15.79% 7.93% 586.53% -6.88% 53.99% 132.58% 191.8%
Net Earnings / Revenue -15.56% -114.11% -138.77% -121.67% -125.92% -91.02% -13.36% -18.54% -468.75% -390.57% -173.66%
Basic Earnings Per Share -$0.13 -$1.12 -$1.85 -$1.66
Diluted Earnings Per Share -$0.13 -$1.12 -$1.85 -$1.66 -$2.612M -$2.961M -$364.9K -$391.8K -$848.3K -$550.9K -$236.9K

Assets & Liabilities

Cash & Short-Term Investments

Loading...

Cash & Equivalents

Loading...

Cash To Operating Expenses Ratio

Loading...

Inventory

Loading...

Receivables

Loading...

Total Short-Term Assets

Loading...

Property, Plant And Equipment

Loading...

Long-Term Investments

Loading...

Total Long-Term Assets

Loading...

Total Assets

Loading...

Net Income To Total Assets Percentage

Loading...

Accounts Payable

Loading...

Short-Term Debt

Loading...

Long Term Debt Due

Loading...

Total Short-Term Liabilities

Loading...

Long-Term Debt

Loading...

Other Long-Term Liabilities

Loading...

Total Long-Term Liabilities

Loading...

Total Liabilities

Loading...

Short-Term To Long-Term Debt Ratio

Loading...

Short-Term Assets To Debt Ratio

Loading...

Long-Term Debt To Net Income Ratio

Loading...

Assets & Liabilities

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Cash & Short-Term Investments $23.87M $27.27M $28.02M $31.81M $49.33M $60.60M $17.38M $9.210M $15.26M $1.330M
YoY Change -12.47% -2.68% -11.9% -35.52% -18.6% 248.68% 88.71% 1047.37%
Cash & Equivalents $23.87M $27.27M $28.02M $31.81M $49.33M $60.60M $17.38M $9.210M $15.26M $1.330M
Short-Term Investments
Other Short-Term Assets $1.854M $2.131M $3.077M $3.400M $3.000M $1.680M $590.0K $420.0K $170.0K $100.0K
YoY Change -13.0% -30.74% -9.5% 13.33% 78.57% 184.75% 40.48% 70.0%
Inventory $6.769M $5.780M $4.038M $2.460M $2.860M $5.440M $4.010M $2.890M $460.0K $670.0K
Prepaid Expenses
Receivables $8.471M $4.704M $12.12M $6.960M $13.13M $6.450M $6.100M $10.66M $770.0K $200.0K
Other Receivables $0.00 $0.00 $0.00 $0.00 $0.00 $30.00K $80.00K $160.0K $10.00K $0.00
Total Short-Term Assets $40.97M $39.89M $47.26M $44.63M $68.31M $74.20M $28.16M $23.33M $16.66M $2.300M
YoY Change 2.7% -15.6% 5.89% -34.67% -7.94% 163.49% 20.7% 624.35%
Property, Plant & Equipment $9.736M $7.901M $7.780M $10.32M $9.730M $12.21M $13.46M $15.12M $8.560M $7.610M
YoY Change 23.22% 1.56% -24.61% 6.06% -20.31% -9.29% -10.98% 12.48%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.438M $6.451M $903.0K $840.0K $240.0K $1.240M $630.0K $300.0K $500.0K
YoY Change -77.71% 614.4% 7.5% -80.65% 96.83% -40.0%
Total Long-Term Assets $16.45M $15.79M $14.73M $18.25M $10.17M $12.65M $14.96M $16.06M $10.52M $10.01M
YoY Change 4.21% 7.15% -19.27% 79.45% -19.6% -15.44% -6.85% 5.09%
Total Assets $57.42M $55.68M $61.99M $62.88M $78.48M $86.85M $43.12M $39.39M $27.18M $12.31M
YoY Change
Accounts Payable $8.926M $9.946M $8.314M $7.090M $12.27M $20.44M $9.600M $6.640M $1.100M $1.250M
YoY Change -10.26% 19.63% 17.26% -42.22% -39.97% 112.92% 44.58% -12.0%
Accrued Expenses $6.887M $8.373M $9.635M $9.300M $5.230M $6.990M $3.810M $2.950M $730.0K $190.0K
YoY Change -17.75% -13.1% 3.6% 77.82% -25.18% 83.46% 29.15% 284.21%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $22.00K $18.70M $2.025M $2.580M $0.00 $4.600M $0.00 $280.0K
YoY Change -99.88% 823.46% -21.51% -100.0% -100.0%
Total Short-Term Liabilities $18.31M $39.68M $21.96M $21.10M $18.56M $32.95M $15.35M $10.81M $1.830M $1.720M
YoY Change -53.86% 80.65% 4.09% 13.69% -43.67% 114.66% 42.0% 6.4%
Long-Term Debt $27.51M $33.45M $51.55M $34.33M $60.34M $42.60M $87.61M $78.27M $0.00 $5.930M
YoY Change -17.76% -35.12% 50.16% -43.11% 41.64% -51.38% 11.93% -100.0%
Other Long-Term Liabilities $118.1M $101.1M $70.61M $55.95M $5.710M $1.220M $8.750M $7.510M $90.00K $0.00
YoY Change 16.8% 43.18% 26.21% 879.86% 368.03% -86.06% 16.51%
Total Long-Term Liabilities $145.6M $134.6M $122.2M $90.28M $66.05M $43.82M $96.36M $85.78M $90.00K $5.930M
YoY Change 8.21% 10.14% 35.32% 36.68% 50.73% -54.52% 12.33% -98.48%
Total Liabilities $163.9M $174.2M $144.1M $111.4M $84.60M $76.77M $111.7M $96.59M $1.920M $7.640M
YoY Change -5.93% 20.89% 29.4% 31.65% 10.2% -31.28% 15.65% -74.87%

Ownership

Basic Shares Outstanding

Loading...

Diluted Shares Outstanding

Loading...

Preferred Stock

Loading...

Treasury Stock Shares

Loading...

Stock Issuance & Repurchase

Loading...

Ownership Data

Concept 2023 2022 2021 2020 2019 2018 2017 2016 2006 2005 2004
Basic Shares Outstanding 61.26M shares 48.73M shares 38.08M shares 33.65M shares
Diluted Shares Outstanding 61.26M shares 48.73M shares 38.08M shares 33.65M shares
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Loading...

Book Value

Loading...

Free Cash Flow

Loading...

Free Cash Flow YoY

Loading...

Free Cash Flow Margin

Loading...

Dividends

Dividends

Loading...

Stock Price

Loading...
Market Cap: $392.98 Million

About Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc. engages in the identifying, developing, and commercializing differentiated products to address unmet medical needs and to solve patients’ therapeutic problems. The company is headquartered in Warren, New Jersey and currently employs 135 full-time employees. The company went IPO on 2018-07-25. The firm is developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies. The company is advancing a product pipeline for the treatment of severe allergic reactions, including anaphylaxis. The company has also developed a product pipeline focused on treating diseases of the central nervous system (CNS). Its PharmFilm technology is comprised of proprietary polymer compositions that serve as film formers to hold active pharmaceutical ingredients (APIs), and excipients in place. Its product portfolio and pipeline include Anaphylm, AQST-108, and Adrenaverse. Its CNS product candidate include Libervant. The Company’s Licensed commercial products and product candidates and other product includes Suboxone, Exservan, KYNMOBI, Zuplenz, Azstarys, Libervant, and Sympazan. Anaphylm is a non-device based, orally delivered epinephrine product candidate.

Industry: Pharmaceutical Preparations Peers: TherapeuticsMD, Inc. Anebulo Pharmaceuticals, Inc. Clearside Biomedical, Inc. EYENOVIA, INC. JOHNSON & JOHNSON Longboard Pharmaceuticals, Inc. Medicine Man Technologies, Inc. Mystic Holdings Inc./NV Odonate Therapeutics, Inc.